Clinical trial
Community Based Trial for AMEVIVE®
NCT00168753 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00168753 |
|---|---|
| Title | Community Based Trial for AMEVIVE® |
| Official title | An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Moderate to Severe Chronic Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Alefacept |
| Enrollment | 114 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 8, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: